Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported routine equity compensation activity. On February 17, he exercised 2,419 restricted stock units, each converting into one share of common stock for no cash consideration, and his common stock holdings increased to 430,705 shares.
On February 18, he sold 1,038 common shares at $15.00 per share solely to cover tax withholding obligations related to the RSU vesting, a non‑discretionary “sell to cover” transaction. After this tax sale, he directly owned 429,667 common shares and 2,419 RSUs subject to continued vesting in equal quarterly installments.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity transactions linked to restricted stock units (RSUs). He sold 1,163 shares of common stock at $15.00 per share to cover tax withholding obligations arising from RSU vesting in a non-discretionary sell-to-cover trade.
In connection with this, 2,419 RSUs were exercised and converted into 2,419 shares of common stock for no cash consideration, with each RSU representing one share upon settlement. The RSUs vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date, subject to continued service.
KalVista Pharmaceuticals chief development officer Christopher Yea reported RSU vesting and related share activity. On February 17, 2026, 1,774 restricted stock units were converted into 1,774 shares of common stock for no cash consideration. On February 18, 2026, 1,109 common shares were sold at $15.00 per share solely to cover tax withholding obligations under a pre-arranged “sell to cover” and were not a discretionary sale.
Palleiko Benjamin L reported multiple insider transaction types in a Form 4 filing for KALV. The filing lists transactions totaling 17,594 shares at a weighted average price of $15.70 per share. Following the reported transactions, holdings were 428,286 shares.
KalVista Pharmaceuticals, Inc. reported that its Chief Operations Officer, Arif Bilal, received a grant of 49,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive 1 share of KalVista common stock upon settlement for no cash consideration.
The RSUs vest in equal installments over four years. Specifically, 1/16 of the total RSUs will vest on each quarterly anniversary of the vesting commencement date, starting May 22, 2026, as long as Bilal’s service with the company does not terminate. Following this grant, he beneficially owns 49,000 RSUs directly.
KalVista Pharmaceuticals reported that its Chief Commercial Officer, Nicole Sweeny, received an equity award in the form of restricted stock units. On January 16, 2026, she was granted 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash payment upon settlement. The RSUs are scheduled to vest in equal installments, with 1/16 of the total amount vesting on each quarterly anniversary of the vesting commencement date, beginning on May 22, 2026, as long as her service with the company continues. Following this grant, she holds 100,000 derivative securities directly in the form of RSUs.
KalVista Pharmaceuticals reported an equity award for its Chief Financial Officer, Brian Piekos. On January 16, 2026, he received 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash consideration upon settlement.
The RSUs are scheduled to vest in equal installments, with 1/16 of the total vesting on each quarterly anniversary of the vesting commencement date starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities in the form of RSUs, held directly.
KalVista Pharmaceuticals’ chief medical officer receives new equity award. Paul K. Audhya, the company’s Chief Medical Officer, reported a grant of 100,000 restricted stock units on January 16, 2026. Each RSU represents the right to receive 1 share of KalVista common stock upon settlement for no cash payment. The RSUs will vest over four years, with 1/16 of the total units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities directly.
KalVista Pharmaceuticals, Inc. reported that its Chief Executive Officer and director, Benjamin L. Palleiko, received a grant of 325,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive one share of KalVista common stock for no cash consideration when the units settle.
According to the vesting terms, 1/16 of the RSUs will vest on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company does not terminate. Following this award, Palleiko directly holds 325,000 derivative securities in the form of RSUs.
KalVista Pharmaceuticals, Inc. received an updated ownership disclosure from Point72-related entities and Steven A. Cohen, who report beneficial ownership of 2,781,902 shares of common stock, representing 5.5% of the company. The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., whose general partner is Point72 Capital Advisors, Inc., all controlled by Mr. Cohen.
This filing is Amendment No. 1 to a prior Schedule 13G and is made to correct the beneficial ownership previously disclosed. The reporting persons state that the securities are not held for the purpose of changing or influencing control of KalVista Pharmaceuticals.